Hospital
Ihc Health Services INC
Ihc Health Services INC was paid $54.08M by Medicaid between Jan 2018 and Nov 2024, across 314 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 67% of everything it billed.
33Billing provider infoIHC HEALTH SERVICES INC
OGDEN, UT 84403
OGDEN, UT 84403
33aNPI1194749580assigned 07/27/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$54.08M
24GClaims855,051
24DCodes billed314
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Utah
Rank by total paid#3 of 6
Median peer was paid$19.91M
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, DENIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 145,866 | $8.52M | |
| 2019 | 157,758 | $8.12M | |
| 2020 | 164,881 | $10.34M | |
| 2021 | 189,025 | $13.06M | |
| 2022 | 170,906 | $12.87M | |
| 2023 | 19,451 | $889K | |
| 2024incomplete | 7,164 | $291K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 67% | 77,548 | 40,006 | $36.06M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 55,828 | 45,692 | $2.06M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 23,838 | 19,708 | $1.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.1% | 26,605 | 23,897 | $1.16M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.6% | 33,571 | 29,454 | $891K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 6,970 | 5,500 | $765K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.3% | 18,271 | 15,657 | $712K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 4,999 | 4,622 | $577K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,688 | 2,462 | $495K |
| 95811 | <1% | 598 | 556 | $338K | |
| 78431 | <1% | 440 | 401 | $306K | |
| 80050 | General health panel | <1% | 3,751 | 3,452 | $295K |
302 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,946 | $293K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,342 | $267K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,905 | $253K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,389 | $238K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,725 | $227K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,787 | $221K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,867 | $212K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,458 | $208K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,493 | $198K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,308 | $176K |
| 80053 | Comprehensive metabolic panel | <1% | 48,881 | $165K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,516 | $146K |
| 85027 | <1% | 5,103 | $138K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,294 | $136K |
| 85610 | <1% | 10,104 | $135K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,240 | $133K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 794 | $133K |
| 81001 | <1% | 23,535 | $125K | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,197 | $121K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,678 | $119K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,498 | $117K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 764 | $115K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,558 | $107K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,527 | $105K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,049 | $101K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 732 | $100K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,574 | $96K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,587 | $96K |
| 72141 | <1% | 682 | $89K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,113 | $79K |
| 86901 | <1% | 2,727 | $78K | |
| 87070 | <1% | 2,411 | $76K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,107 | $75K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 541 | $73K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 552 | $73K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,228 | $72K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,117 | $72K |
| 59025 | Fetal non-stress test | <1% | 1,352 | $71K |
| 87186 | <1% | 4,111 | $68K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 7,076 | $68K |
| 73562 | <1% | 1,830 | $67K | |
| 73630 | <1% | 1,794 | $64K | |
| 74018 | <1% | 1,666 | $64K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,811 | $63K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 180 | $61K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,234 | $60K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 548 | $59K |
| 84702 | <1% | 8,732 | $59K | |
| 73130 | <1% | 1,305 | $59K | |
| 72100 | <1% | 1,045 | $59K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 644 | $58K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 745 | $57K |
| 77066 | Tomosynthesis, mammo | <1% | 552 | $57K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 629 | $56K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,170 | $56K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,825 | $56K |
| 76830 | Ultrasound, transvaginal | <1% | 1,709 | $55K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,019 | $55K |
| 73030 | <1% | 1,403 | $54K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,046 | $54K |
| 73610 | <1% | 1,528 | $53K | |
| 83880 | <1% | 5,971 | $52K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,148 | $52K |
| 82565 | <1% | 1,814 | $52K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,508 | $52K |
| 96376 | <1% | 3,285 | $49K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 84 | $47K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,294 | $44K |
| 82330 | <1% | 2,215 | $44K | |
| 73110 | <1% | 991 | $43K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,862 | $39K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,106 | $39K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,783 | $39K |
| 87081 | <1% | 2,256 | $38K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 468 | $37K |
| C1769 | Guide wire | <1% | 1,436 | $37K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,163 | $37K |
| 93971 | <1% | 1,672 | $36K | |
| 94729 | <1% | 364 | $35K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,133 | $35K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,711 | $35K |
| 93017 | <1% | 1,035 | $34K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,898 | $34K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,176 | $33K |
| 84703 | <1% | 3,442 | $33K | |
| 95806 | <1% | 437 | $32K | |
| 88304 | <1% | 1,235 | $32K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,745 | $32K |
| 73221 | <1% | 223 | $30K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,464 | $30K |
| 81025 | <1% | 673 | $29K | |
| 94060 | <1% | 448 | $29K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 494 | $28K |
| 97597 | <1% | 553 | $28K | |
| 84484 | <1% | 10,462 | $27K | |
| 94762 | <1% | 290 | $26K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,090 | $25K |
| 73090 | <1% | 408 | $25K | |
| 76770 | <1% | 750 | $25K | |
| 83690 | <1% | 14,683 | $25K | |
| 97162 | <1% | 592 | $24K | |
| J3490 | Unclassified drugs | <1% | 429 | $23K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,481 | $23K |
| 73080 | <1% | 395 | $23K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,540 | $23K |
| 73502 | <1% | 738 | $22K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,501 | $22K |
| 76642 | <1% | 1,417 | $22K | |
| 70486 | <1% | 586 | $21K | |
| 74019 | <1% | 578 | $20K | |
| 83605 | <1% | 13,051 | $20K | |
| 93970 | <1% | 410 | $19K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 164 | $19K |
| 87077 | <1% | 1,904 | $18K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 902 | $17K |
| 80061 | Lipid panel | <1% | 3,761 | $17K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,375 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,495 | $17K |
| 82805 | <1% | 767 | $16K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 39 | $16K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,896 | $16K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 968 | $15K |
| 80081 | <1% | 136 | $15K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 825 | $15K |
| 76801 | <1% | 1,336 | $14K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 755 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,303 | $13K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,764 | $13K |
| 87631 | <1% | 355 | $13K | |
| 0001A | <1% | 461 | $12K | |
| 12001 | <1% | 501 | $12K | |
| 0002A | <1% | 434 | $12K | |
| 86850 | <1% | 1,844 | $12K | |
| 73590 | <1% | 495 | $12K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 952 | $12K |
| 77065 | Tomosynthesis, mammo | <1% | 188 | $11K |
| 97602 | <1% | 348 | $11K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 933 | $11K |
| 0482T | <1% | 40 | $11K | |
| 86140 | <1% | 7,255 | $11K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 960 | $10K |
| 87660 | <1% | 273 | $10K | |
| 82728 | <1% | 1,696 | $10K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,426 | $10K |
| 82247 | <1% | 1,352 | $9K | |
| 87040 | <1% | 4,696 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,249 | $9K |
| 73140 | <1% | 93 | $9K | |
| 87088 | <1% | 3,348 | $9K | |
| 84439 | <1% | 2,313 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,689 | $8K |
| 71250 | <1% | 168 | $8K | |
| 97161 | <1% | 66 | $8K | |
| 85379 | <1% | 3,520 | $8K | |
| 83540 | <1% | 1,398 | $7K | |
| 78434 | <1% | 437 | $7K | |
| 93225 | <1% | 123 | $6K | |
| 88307 | <1% | 143 | $6K | |
| 72131 | <1% | 211 | $6K | |
| 93922 | <1% | 199 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,826 | $6K |
| 72040 | <1% | 172 | $6K | |
| 85018 | <1% | 89 | $5K | |
| 82803 | <1% | 2,002 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,548 | $5K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 257 | $5K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 424 | $5K |
| 87075 | <1% | 731 | $5K | |
| 84156 | <1% | 876 | $5K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 225 | $5K |
| 84466 | <1% | 1,354 | $4K | |
| 87210 | <1% | 333 | $4K | |
| 29581 | <1% | 36 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,615 | $4K |
| 0031A | <1% | 196 | $4K | |
| 82570 | <1% | 1,855 | $4K | |
| 82607 | <1% | 1,499 | $4K | |
| 87480 | <1% | 273 | $4K | |
| 83735 | <1% | 4,923 | $4K | |
| 83516 | <1% | 329 | $4K | |
| 80069 | <1% | 463 | $4K | |
| 80076 | <1% | 696 | $4K | |
| 85651 | <1% | 3,616 | $4K | |
| 97163 | <1% | 40 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,540 | $3K |
| 86900 | <1% | 1,907 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 111 | $3K |
| 70498 | <1% | 382 | $3K | |
| 89060 | <1% | 45 | $3K | |
| 12002 | <1% | 114 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 125 | $3K |
| 76820 | <1% | 36 | $3K | |
| 12011 | <1% | 175 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 61 | $3K |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 28 | $3K |
| 77062 | <1% | 106 | $2K | |
| 87807 | <1% | 14 | $2K | |
| 72170 | <1% | 74 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 169 | $2K |
| 10060 | <1% | 143 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 165 | $2K |
| 82550 | <1% | 1,319 | $2K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 480 | $2K |
| 82731 | <1% | 28 | $2K | |
| 85730 | <1% | 1,445 | $2K | |
| 84100 | <1% | 1,405 | $2K | |
| 90715 | <1% | 1,033 | $2K | |
| 83655 | <1% | 137 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 95 | $2K |
| 86364 | <1% | 13 | $2K | |
| 83615 | <1% | 650 | $2K | |
| 89050 | <1% | 46 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 40 | $2K |
| 87449 | <1% | 129 | $2K | |
| 82784 | <1% | 437 | $1K | |
| 84132 | <1% | 792 | $1K | |
| 88342 | <1% | 43 | $1K | |
| 82010 | <1% | 563 | $1K | |
| 82043 | <1% | 815 | $1K | |
| 86803 | <1% | 671 | $1K | |
| 93242 | <1% | 26 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 27 | $1K |
| 0100U | <1% | 28 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 924 | $1K |
| 83970 | <1% | 375 | $1K | |
| 76536 | <1% | 16 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,013 | $1K |
| 87147 | <1% | 420 | $1K | |
| 80074 | <1% | 56 | $1K | |
| 72146 | <1% | 12 | $1K | |
| 80164 | <1% | 176 | $1K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 13 | $995.18 |
| 70496 | <1% | 391 | $923.69 | |
| 82140 | <1% | 417 | $915.88 | |
| 82950 | <1% | 306 | $883.61 | |
| 84478 | <1% | 173 | $879.57 | |
| 73552 | <1% | 27 | $827.02 | |
| 96367 | <1% | 291 | $707.90 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 47 | $692.34 |
| 10061 | <1% | 25 | $612.18 | |
| 84481 | <1% | 28 | $612.00 | |
| 91300 | <1% | 46 | $609.13 | |
| 82105 | <1% | 102 | $548.21 | |
| 84480 | <1% | 35 | $507.76 | |
| 81003 | <1% | 207 | $500.26 | |
| 89051 | <1% | 18 | $492.87 | |
| 82248 | <1% | 143 | $483.37 | |
| 84460 | <1% | 300 | $450.93 | |
| 93226 | <1% | 101 | $410.27 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 322 | $405.06 |
| 84550 | <1% | 160 | $390.79 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 154 | $363.74 |
| 86780 | <1% | 67 | $346.10 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 90 | $271.44 |
| 76870 | <1% | 12 | $258.71 | |
| 88302 | <1% | 59 | $250.86 | |
| 87324 | <1% | 47 | $247.86 | |
| 94726 | <1% | 38 | $238.67 | |
| 85007 | <1% | 658 | $220.65 | |
| 29125 | <1% | 75 | $216.66 | |
| 84450 | <1% | 260 | $196.12 | |
| 84403 | <1% | 13 | $195.01 | |
| G0378 | Hospital observation service, per hour | <1% | 375 | $192.29 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 44 | $188.53 |
| 77061 | <1% | 14 | $150.67 | |
| 83993 | <1% | 12 | $146.02 | |
| 43235 | <1% | 13 | $143.99 | |
| 86038 | <1% | 49 | $124.48 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 80 | $112.52 |
| 80197 | <1% | 107 | $110.51 | |
| 86706 | <1% | 69 | $100.73 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 85 | $92.35 |
| 83520 | <1% | 16 | $79.93 | |
| 87510 | <1% | 273 | $68.22 | |
| 82947 | <1% | 54 | $57.17 | |
| 82977 | <1% | 12 | $42.00 | |
| 86431 | <1% | 16 | $36.27 | |
| 87340 | <1% | 494 | $26.88 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 917 | $17.02 |
| 86704 | <1% | 27 | $13.39 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 154 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 149 | $0.00 |
| 90686 | 0% | 221 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 59 | $0.00 |
| 78492 | 0% | 27 | $0.00 | |
| 87205 | 0% | 15 | $0.00 | |
| 96415 | 0% | 34 | $0.00 | |
| 82657 | 0% | 35 | $0.00 | |
| 82746 | 0% | 12 | $0.00 | |
| 78499 | 0% | 27 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 164 | $0.00 |
| 84145 | 0% | 97 | $0.00 | |
| 43249 | 0% | 315 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 32 | $0.00 |
| 96417 | 0% | 21 | $0.00 | |
| 86923 | 0% | 20 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 15 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 12 | $0.00 |
| 76937 | 0% | 26 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 65 | $0.00 |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 27 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, DENIS (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ihc Health Services, INC. | Murray, UT | $68.77M |
| Ihc Health Services, INC. | St George, UT | $65.78M |
| Ihc Health Services, INC. | Provo, UT | $44.35M |
| Ihc Health Services INC | Logan, UT | $25.34M |
| Ihc Health Services, INC. | Cedar City, UT | $20.40M |
| Ihc Health Services, INC. | Salt Lake City, UT | $19.91M |
| Ihc Health Services, INC. | American Fork, UT | $17.19M |
| Ihc Health Services INC | Riverton, UT | $15.31M |
| Ihc Health Services INC | Sandy, UT | $11.66M |
| Ihc Health Services, INC. | Layton, UT | $11.61M |
| Ihc Health Services, INC. | Burley, ID | $5.14M |
| Ihc Health Services INC | Murray, UT | $4.64M |
| Ihc Health Services INC | St George, UT | $4.35M |
| Ihc Health Services INC | Heber City, UT | $4.31M |
| Ihc Health Services, INC. | Orem, UT | $4.18M |
| Ihc Health Services, INC. | Richfield, UT | $3.87M |
| Ihc Health Services INC | Tremonton, UT | $3.55M |
| Ihc Health Services, INC. | Spanish Fork, UT | $3.49M |
| Ihc Health Services INC | Park City, UT | $2.53M |
| Ihc Health Services, INC. | Mt Pleasant, UT | $2.34M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.